Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study)

SIMPLE SUMMARY: Afatinib has been approved for patients with lung cancer carrying uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another second-generation inhibitor, has also shown promising potential for these mutations. This is the first and largest comparative study...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hong-Shuai, Wang, Shou-Zheng, Xu, Hai-Yan, Yan, Xiang, Zhang, Jin-Yao, Lei, Si-Yu, Li, Teng, Hao, Xue-Zhi, Zhang, Tao, Yang, Guang-Jian, Zhou, Li-Qiang, Liu, Peng, Wang, Yu-Ying, Hu, Xing-Sheng, Xing, Pu-Yuan, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656097/
https://www.ncbi.nlm.nih.gov/pubmed/36358728
http://dx.doi.org/10.3390/cancers14215307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656097/
https://www.ncbi.nlm.nih.gov/pubmed/36358728
http://dx.doi.org/10.3390/cancers14215307

Ejemplares similares